Onconetix (ONCO) Cash & Equivalents (2021 - 2026)

Onconetix (ONCO) has reported Cash & Equivalents for 6 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 135.61% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (up 135.61% YoY), while the FY2025 annual figure was $5.2 million, up 707.53% from the prior year.
• Cash & Equivalents fell to $3.7 million in Q1 2026 per ONCO's latest filing, from $5.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $29.1 million in Q3 2022 and bottomed at $283515.0 in Q2 2025.
• Historically, Cash & Equivalents has averaged $9.2 million across 5 years, with a median of $4.6 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 1235.39% — and 2024, when it tumbled 95.54%.
• Onconetix's Cash & Equivalents stood at $25.8 million in 2022, then sank by 82.32% to $4.6 million in 2023, then tumbled by 85.8% to $646500.0 in 2024, then soared by 707.53% to $5.2 million in 2025, then retreated by 28.82% to $3.7 million in 2026.
• Business Quant data shows ONCO's Cash & Equivalents at $3.7 million in Q1 2026, $5.2 million in Q4 2025, and $836556.0 in Q3 2025.